/INBX
INBX Stock - Inhibrx Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$86.13+0.95%
+$0.81 (+0.95%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $94.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INBX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$85.27 – $86.99
TARGET (TP)$99.05
STOP LOSS$79.24
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$94.47
52W Low$10.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $200,000 | $1.80M | $2.19M | $7.13M | $12.81M |
| Gross Profit | $-2,085,000 | $609,000 | $-107,994,000 | $4.44M | $-60,687,000 |
| Gross Margin | -1042.5% | 33.8% | -4926.7% | 62.3% | -473.8% |
| Operating Income | $-331,448,000 | $-219,221,000 | $-129,117,000 | $-76,564,000 | $-67,443,000 |
| Net Income | $1.69B | $-241,361,000 | $-145,226,000 | $-81,768,000 | $-75,637,000 |
| Net Margin | 843786.0% | -13408.9% | -6625.3% | -1147.6% | -590.5% |
| EPS | $116.58 | $-5.12 | $-3.62 | $-2.15 | $-2.99 |
Company Overview
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 23rd 2024 | JMP Securities | Initiation | Market Perform | - |
| January 23rd 2024 | JMP Securities | Downgrade | Market Perform | - |
Earnings History & Surprises
INBXBeat Rate
28%
Last 18 quarters
Avg Surprise
+188.6%
EPS vs Estimate
Beats / Misses
5/13
Last 12 quarters
Latest EPS
$-2.28
Q4 2025
EPS Surprise History
Q1 24
-61.7%
$-1.73vs$-1.07
Q2 24
-38.5%
$-1.44vs$-1.04
Q3 24
+3585.6%
$125.48vs$-3.60
Q4 24
+7.2%
$-2.84vs$-3.06
Q1 25
-7.3%
$-3.09vs$-2.88
Q2 25
-9.8%
$-2.80vs$-2.55
Q3 25
+36.6%
$-1.85vs$-2.92
Q4 25
-9.6%
$-2.28vs$-2.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-2.08 | $-2.28 | -9.6% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-2.92 | $-1.85 | +36.6% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-2.55 | $-2.80 | -9.8% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-2.88 | $-3.09 | -7.3% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-3.06 | $-2.84 | +7.2% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-3.60 | $125.48 | +3585.6% | ✓ BEAT |
Q2 2024 | Jun 3, 2024 | $-1.04 | $-1.44 | -38.5% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-1.07 | $-1.73 | -61.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.01 | $-1.10 | -8.9% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-1.02 | $-1.08 | -5.9% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.84 | $-1.12 | -33.3% | ✗ MISS |
Q1 2023 | Mar 6, 2023 | $-0.80 | $-0.95 | -18.7% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-1.01 | $-0.90 | +10.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.84 | $-0.97 | -15.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.62 | $-0.80 | -29.0% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.53 | $-0.55 | -3.8% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.57 | $-0.54 | +5.3% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.51 | $-0.55 | -7.8% | ✗ MISS |
Latest News
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026
➖ NeutralBenzinga•Dec 16, 2025, 10:03 PM
Inhibrx Biosciences Q3 EPS $(2.28) Misses $(1.72) Estimate, Cash And Cash Equivalents Of $153.1M
📉 NegativeBenzinga•Nov 14, 2025, 11:04 AM
Inhibrx shares are trading higher after the company said Ozekibart met its primary endpoint in chondrosarcoma, showing a statistically significant and clinically meaningful improvement in progression-free survival versus placebo.
📈 PositiveBenzinga•Oct 24, 2025, 02:46 PM
Inhibrx surges on meeting key goal in trial for ozekibart for rare bone cancer
📈 PositiveSeeking Alpha•Oct 23, 2025, 09:05 PM
Inhibrx Biosciences Shares Resume
➖ NeutralBenzinga•Oct 23, 2025, 08:44 PM
Inhibrx shares are trading higher after the company said Ozekibart met its primary endpoint in chondrosarcoma, showing a statistically significant and clinically meaningful improvement in progression-free survival versus placebo.
📈 PositiveBenzinga•Oct 23, 2025, 08:44 PM
Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 23, 2025, 08:25 PM
Inhibrx Biosciences Reports Topline Results From Registrational ChonDRAgon Study Investigating Ozekibart As Single Agent Vs. Placebo In Patients With Unresectable Chondrosarcoma; Ozekibart Meets Primary Endpoint In Chondrosarcoma
📈 PositiveBenzinga•Oct 23, 2025, 08:20 PM
Trading Halt: Halted at 4:00:10 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 23, 2025, 08:00 PM
INBX stock has given up its prior gain. Inhibrx Biosciences shares were trading higher after the company announced that it will present topline results from the registrational ChonDRAgon study investigating ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.
➖ NeutralBenzinga•Oct 22, 2025, 09:29 PM
Inhibrx Biosciences shares are trading higher after the company announced that it will present topline results from the registrational ChonDRAgon study investigating ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.
📈 PositiveBenzinga•Oct 22, 2025, 08:59 PM
Inhibrx Biosciences To Webcast ChonDRAgon Study Results For Ozekibart In Chondrosarcoma On October 23
➖ NeutralBenzinga•Oct 22, 2025, 08:02 PM
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform
➖ NeutralBenzinga•Aug 22, 2025, 12:55 PM
Inhibrx Biosciences Beats Earnings
📈 PositiveThe Motley Fool•Aug 13, 2025, 08:37 PM
Frequently Asked Questions about INBX
What is INBX's current stock price?
Inhibrx Biosciences, Inc. (INBX) is currently trading at $86.13 per share. The stock has moved +0.95% today.
What is the analyst price target for INBX?
No analyst price targets are currently available for this stock.
What sector is Inhibrx Biosciences, Inc. in?
Inhibrx Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INBX's market cap?
Inhibrx Biosciences, Inc. has a market capitalization of $1.25 billion, making it a small-cap company.
Does INBX pay dividends?
No, Inhibrx Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
CVAC
CureVac N.V.
$4.16
Mkt Cap: $0.9B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
Explore stocks similar to INBX for comparison